Company Description
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue.
Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease.
The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015.
The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022.
Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
| Country | United States |
| IPO Date | Mar 1, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. |
Contact Details
Address: 110 Allen Road Basking Ridge, New Jersey United States | |
| Website | https://www.lisata.com |
Stock Details
| Ticker Symbol | LSTA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000320017 |
| CUSIP Number | 128058302 |
| ISIN Number | US1280583022 |
| Employer ID | 22-2343568 |
| SIC Code | 8090 |
Key Executives
| Name | Position |
|---|---|
| Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. | President, Chief Executive Officer & Director |
| Dr. Kristen K. Buck M.D. | Executive Vice President of R&D and Chief Medical Officer |
| Dr. William K. Sietsema Ph.D. | Vice President of Global Regulatory Affairs |
| Gail Holler | Vice President of Human Resources |
| Gregory S. Berkin | Chief Information & Data Protection Officer |
| James Nisco | Senior Vice President of Finance, Treasurer, CAO & Principal Financial and Accounting Officer |
| John D. Menditto | Vice President of Investor Relations & Corporate Communications |
| Tariq Imam | Vice President of Business Development & Operations and Corporate Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 03, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 02, 2024 | 4 | Filing |
| Oct 02, 2024 | 4 | Filing |
| Oct 02, 2024 | 4 | Filing |
| Aug 21, 2024 | 424B5 | Filing |
| Aug 12, 2024 | 10-Q | Quarterly Report |
| Aug 12, 2024 | 8-K | Current Report |
| Jul 15, 2024 | S-8 | Filing |